These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 20357382)

  • 1. Effect of ranolazine on A1C and glucose levels in hyperglycemic patients with non-ST elevation acute coronary syndrome.
    Chisholm JW; Goldfine AB; Dhalla AK; Braunwald E; Morrow DA; Karwatowska-Prokopczuk E; Belardinelli L
    Diabetes Care; 2010 Jun; 33(6):1163-8. PubMed ID: 20357382
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the glycometabolic effects of ranolazine in patients with and without diabetes mellitus in the MERLIN-TIMI 36 randomized controlled trial.
    Morrow DA; Scirica BM; Chaitman BR; McGuire DK; Murphy SA; Karwatowska-Prokopczuk E; McCabe CH; Braunwald E;
    Circulation; 2009 Apr; 119(15):2032-9. PubMed ID: 19349325
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of ranolazine in patients with chronic angina observations from the randomized, double-blind, placebo-controlled MERLIN-TIMI (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Segment Elevation Acute Coronary Syndromes) 36 Trial.
    Wilson SR; Scirica BM; Braunwald E; Murphy SA; Karwatowska-Prokopczuk E; Buros JL; Chaitman BR; Morrow DA
    J Am Coll Cardiol; 2009 Apr; 53(17):1510-6. PubMed ID: 19389561
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial.
    Morrow DA; Scirica BM; Karwatowska-Prokopczuk E; Murphy SA; Budaj A; Varshavsky S; Wolff AA; Skene A; McCabe CH; Braunwald E;
    JAMA; 2007 Apr; 297(16):1775-83. PubMed ID: 17456819
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolic efficiency with ranolazine for less ischemia in non-ST elevation acute coronary syndromes (MERLIN TIMI-36) study.
    Melloni C; Newby LK
    Expert Rev Cardiovasc Ther; 2008 Jan; 6(1):9-16. PubMed ID: 18095903
    [TBL] [Abstract][Full Text] [Related]  

  • 6. B-type natriuretic peptide and the effect of ranolazine in patients with non-ST-segment elevation acute coronary syndromes: observations from the MERLIN-TIMI 36 (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST Elevation Acute Coronary-Thrombolysis In Myocardial Infarction 36) trial.
    Morrow DA; Scirica BM; Sabatine MS; de Lemos JA; Murphy SA; Jarolim P; Theroux P; Bode C; Braunwald E
    J Am Coll Cardiol; 2010 Mar; 55(12):1189-1196. PubMed ID: 20298924
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of ranolazine, an antianginal agent with novel electrophysiological properties, on the incidence of arrhythmias in patients with non ST-segment elevation acute coronary syndrome: results from the Metabolic Efficiency With Ranolazine for Less Ischemia in Non ST-Elevation Acute Coronary Syndrome Thrombolysis in Myocardial Infarction 36 (MERLIN-TIMI 36) randomized controlled trial.
    Scirica BM; Morrow DA; Hod H; Murphy SA; Belardinelli L; Hedgepeth CM; Molhoek P; Verheugt FW; Gersh BJ; McCabe CH; Braunwald E
    Circulation; 2007 Oct; 116(15):1647-52. PubMed ID: 17804441
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ischemia detected on continuous electrocardiography after acute coronary syndrome: observations from the MERLIN-TIMI 36 (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Elevation Acute Coronary Syndrome-Thrombolysis In Myocardial Infarction 36) trial.
    Scirica BM; Morrow DA; Budaj A; Dalby AJ; Mohanavelu S; Qin J; Aroesty J; Hedgepeth CM; Stone PH; Braunwald E
    J Am Coll Cardiol; 2009 Apr; 53(16):1411-21. PubMed ID: 19371824
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical features and outcomes of women with unstable ischemic heart disease: observations from metabolic efficiency with ranolazine for less ischemia in non-ST-elevation acute coronary syndromes-thrombolysis in myocardial infarction 36 (MERLIN-TIMI 36).
    Mega JL; Hochman JS; Scirica BM; Murphy SA; Sloan S; McCabe CH; Merlini P; Morrow DA
    Circulation; 2010 Apr; 121(16):1809-17. PubMed ID: 20385930
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospective evaluation of pregnancy-associated plasma protein-a and outcomes in patients with acute coronary syndromes.
    Bonaca MP; Scirica BM; Sabatine MS; Jarolim P; Murphy SA; Chamberlin JS; Rhodes DW; Southwick PC; Braunwald E; Morrow DA
    J Am Coll Cardiol; 2012 Jul; 60(4):332-8. PubMed ID: 22813612
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of ranolazine in patients with type 2 diabetes mellitus and chronic stable angina: results from the TERISA randomized clinical trial (Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina).
    Kosiborod M; Arnold SV; Spertus JA; McGuire DK; Li Y; Yue P; Ben-Yehuda O; Katz A; Jones PG; Olmsted A; Belardinelli L; Chaitman BR
    J Am Coll Cardiol; 2013 May; 61(20):2038-45. PubMed ID: 23500237
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relation of T-wave alternans to mortality and nonsustained ventricular tachycardia in patients with non-ST-segment elevation acute coronary syndrome from the MERLIN-TIMI 36 trial of ranolazine versus placebo.
    Nieminen T; Scirica BM; Pegler JR; Tavares C; Pagotto VP; Kanas AF; Sobrado MF; Nearing BD; Umez-Eronini AA; Morrow DA; Belardinelli L; Verrier RL
    Am J Cardiol; 2014 Jul; 114(1):17-23. PubMed ID: 24852915
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of ranolazine on disease-specific health status and quality of life among patients with acute coronary syndromes: results from the MERLIN-TIMI 36 randomized trial.
    Arnold SV; Morrow DA; Wang K; Lei Y; Mahoney EM; Scirica BM; Braunwald E; Cohen DJ;
    Circ Cardiovasc Qual Outcomes; 2008 Nov; 1(2):107-15. PubMed ID: 20031797
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical features, use of evidence-based therapies, and cardiovascular outcomes among patients with chronic kidney disease following non-ST-elevation acute coronary syndrome.
    Rhee JW; Wiviott SD; Scirica BM; Gibson CM; Murphy SA; Bonaca MP; Morrow DA; Mega JL
    Clin Cardiol; 2014 Jun; 37(6):350-6. PubMed ID: 24481910
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of ranolazine on atrial fibrillation in patients with non-ST elevation acute coronary syndromes: observations from the MERLIN-TIMI 36 trial.
    Scirica BM; Belardinelli L; Chaitman BR; Waks JW; Volo S; Karwatowska-Prokopczuk E; Murphy SA; Cheng ML; Braunwald E; Morrow DA
    Europace; 2015 Jan; 17(1):32-7. PubMed ID: 25210025
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The risk of sudden cardiac death in patients with non-ST elevation acute coronary syndrome and prolonged QTc interval: effect of ranolazine.
    Karwatowska-Prokopczuk E; Wang W; Cheng ML; Zeng D; Schwartz PJ; Belardinelli L
    Europace; 2013 Mar; 15(3):429-36. PubMed ID: 23258816
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of a novel anti-ischemic agent in acute coronary syndromes: design and rationale for the Metabolic Efficiency with Ranolazine for Less Ischemia in Non-ST-elevation acute coronary syndromes (MERLIN)-TIMI 36 trial.
    Morrow DA; Scirica BM; Karwatowska-Prokopczuk E; Skene A; McCabe CH; Braunwald E;
    Am Heart J; 2006 Jun; 151(6):1186.e1-9. PubMed ID: 16781216
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Osteoprotegerin and cardiovascular mortality in patients with non-ST elevation acute coronary syndromes.
    Røysland R; Bonaca MP; Omland T; Sabatine M; Murphy SA; Scirica BM; Bjerre M; Flyvbjerg A; Braunwald E; Morrow DA
    Heart; 2012 May; 98(10):786-91. PubMed ID: 22373720
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of ST2 in non-ST-elevation acute coronary syndrome in the MERLIN-TIMI 36 trial.
    Kohli P; Bonaca MP; Kakkar R; Kudinova AY; Scirica BM; Sabatine MS; Murphy SA; Braunwald E; Lee RT; Morrow DA
    Clin Chem; 2012 Jan; 58(1):257-66. PubMed ID: 22096031
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of ranolazine in patients with type 2 diabetes mellitus and chronic stable angina according to baseline hemoglobin A1c.
    Arnold SV; McGuire DK; Spertus JA; Li Y; Yue P; Ben-Yehuda O; Belardinelli L; Jones PG; Olmsted A; Chaitman BR; Kosiborod M
    Am Heart J; 2014 Oct; 168(4):457-465.e2. PubMed ID: 25262254
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.